Marrone Bio Innovations Inc. (NASDAQ:MBII) has been assigned a consensus rating of “Hold” from the six ratings firms that are covering the company. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $5.50.

Several analysts have recently weighed in on MBII shares. Zacks Investment Research upgraded shares of Marrone Bio Innovations from a “sell” rating to a “hold” rating in a research report on Wednesday, October 12th. Jefferies Group boosted their price objective on shares of Marrone Bio Innovations from $1.50 to $2.50 and gave the stock a “hold” rating in a research report on Wednesday, November 23rd.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this piece of content can be read at http://www.dailypolitical.com/2016/11/30/marrone-bio-innovations-inc-mbii-receives-5-50-consensus-pt-from-analysts.html.

Shares of Marrone Bio Innovations (NASDAQ:MBII) opened at 2.33 on Monday. Marrone Bio Innovations has a 52-week low of $0.60 and a 52-week high of $2.79. The company’s 50-day moving average is $2.03 and its 200 day moving average is $1.33. The firm’s market cap is $57.45 million.

Marrone Bio Innovations (NASDAQ:MBII) last issued its quarterly earnings data on Monday, November 14th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.07. Marrone Bio Innovations had a negative return on equity of 2,083.14% and a negative net margin of 258.51%. On average, analysts expect that Marrone Bio Innovations will post ($1.17) earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in Marrone Bio Innovations stock. Ardsley Advisory Partners purchased a new position in Marrone Bio Innovations Inc. (NASDAQ:MBII) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 774,438 shares of the company’s stock, valued at approximately $1,324,000. Ardsley Advisory Partners owned about 3.15% of Marrone Bio Innovations as of its most recent SEC filing. Hedge funds and other institutional investors own 37.87% of the company’s stock.

Marrone Bio Innovations Company Profile

Marrone Bio Innovations, Inc offers bio-based pest management and plant health products. The Company’s bio-based products include naturally occurring microorganisms, such as bacteria, fungi and plant extracts. It sells its products to crop protection market. Its four crop protection products include Regalia, Grandevo, Venerate and Majestene.

5 Day Chart for NASDAQ:MBII

Receive News & Ratings for Marrone Bio Innovations Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations Inc. and related companies with MarketBeat.com's FREE daily email newsletter.